DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Buprenorphine hydrochloride; naloxone hydrochlorideis the generic ingredient in five branded drugs marketed by Bdsi, Alvogen Pine Brook, Dr Reddys Labs Sa, Mylan Technologies, Indivior Inc, Teva Pharms Usa, Actavis Elizabeth, Amneal Pharms, Ethypharm Usa Corp, Hikma, Lannett Co Inc, Mayne Pharma Inc, Rhodes Pharms, Specgx Llc, Sun Pharm, Wes Pharma Inc, and Orexo Us Inc, and is included in twenty-one NDAs. There are seventeen patents protecting this compound and nine Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.
Buprenorphine hydrochloride; naloxone hydrochloride has three hundred and fifty patent family members in thirty-seven countries.
There are twenty-nine drug master file entries for buprenorphine hydrochloride; naloxone hydrochloride. Twenty-two suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for buprenorphine hydrochloride; naloxone hydrochloride
|Drug Master File Entries:||29|
|Suppliers / Packagers:||22|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for buprenorphine hydrochloride; naloxone hydrochloride|
|DailyMed Link:||buprenorphine hydrochloride; naloxone hydrochloride at DailyMed|
Recent Clinical Trials for buprenorphine hydrochloride; naloxone hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
|Milton S. Hershey Medical Center||Early Phase 1|
|IMEA Paris||Phase 2|
|National Institute of Drug Abuse||Phase 2|
Generic filers with tentative approvals for BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for buprenorphine hydrochloride; naloxone hydrochloride
|Drug Class||Partial Opioid Agonist |
|Mechanism of Action||Partial Opioid Agonists |
Paragraph IV (Patent) Challenges for BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE
|Country||Patent Number||Estimated Expiration|
|European Patent Office||3566692||Start Trial|
|European Patent Office||1456702||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.